CL2017002346A1 - Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer - Google Patents

Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer

Info

Publication number
CL2017002346A1
CL2017002346A1 CL2017002346A CL2017002346A CL2017002346A1 CL 2017002346 A1 CL2017002346 A1 CL 2017002346A1 CL 2017002346 A CL2017002346 A CL 2017002346A CL 2017002346 A CL2017002346 A CL 2017002346A CL 2017002346 A1 CL2017002346 A1 CL 2017002346A1
Authority
CL
Chile
Prior art keywords
peptides
new
cancer
relates
present
Prior art date
Application number
CL2017002346A
Other languages
English (en)
Inventor
Toni Weinschenk
Jens Fritsche
Andrea Mahr
Oliver Schoor
Harpreet Singh
Claudia Wagner
Martina Ott
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61866862&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017002346(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB201504502A external-priority patent/GB201504502D0/en
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of CL2017002346A1 publication Critical patent/CL2017002346A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001174—Proteoglycans, e.g. glypican, brevican or CSPG4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4213—CD74, Ii, MHC class II invariant chain or MHC class II gamma chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)

Abstract

<p>La presente invención se refiere a péptidos, proteínas, ácidos nucleicos y células destinados a la utilización en métodos inmunoterapéuticos. En particular, la presente invención se refiere a la inmunoterapia contra el cáncer. La presente invención se refiere asimismo a epítopos peptídicos para linfocitos T asociados a tumores, solos o en combinación con otros péptidos asociados a tumores que, por ejemplo, pueden servir como principios activos farmacéuticos en composiciones vacunales destinadas a estimular respuestas inmunitarias antitumorales, o a estimular ex vivo linfocitos T que después serán transferidos a los pacientes. Los péptidos unidos a moléculas del complejo mayor de histocompatibilidad (MHC), o los péptidos como tales, también pueden ser dianas de anticuerpos, de receptores de linfocitos T solubles, y de otras moléculas de unión.</p>
CL2017002346A 2015-03-17 2017-09-15 Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer CL2017002346A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562134253P 2015-03-17 2015-03-17
GB201504502A GB201504502D0 (en) 2015-03-17 2015-03-17 Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers

Publications (1)

Publication Number Publication Date
CL2017002346A1 true CL2017002346A1 (es) 2018-03-09

Family

ID=61866862

Family Applications (5)

Application Number Title Priority Date Filing Date
CL2017002346A CL2017002346A1 (es) 2015-03-17 2017-09-15 Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer
CL2018002427A CL2018002427A1 (es) 2015-03-17 2018-08-24 Péptidos y combinación de péptidos para el uso de la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer. (divisional solicitud 201702346)
CL2020001675A CL2020001675A1 (es) 2015-03-17 2020-06-19 Péptidos asociados a tumor y su uso en la inmunoterapia contra el cáncer (divisional solicitud 201702346)
CL2021000624A CL2021000624A1 (es) 2015-03-17 2021-03-15 Péptidos asociados a tumor que se unen al complejo mayor de histocompatibilidad (mhc) y/o inducen la reacción cruzada de linfocitos t y sus usos en la inmunoterapia contra el cáncer (divisional de la solicitud no. 201702346)
CL2021000623A CL2021000623A1 (es) 2015-03-17 2021-03-15 Péptidos asociados a tumor y sus usos en la inmunoterapia contra el cáncer (divisional de la solicitud no. 201702346)

Family Applications After (4)

Application Number Title Priority Date Filing Date
CL2018002427A CL2018002427A1 (es) 2015-03-17 2018-08-24 Péptidos y combinación de péptidos para el uso de la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer. (divisional solicitud 201702346)
CL2020001675A CL2020001675A1 (es) 2015-03-17 2020-06-19 Péptidos asociados a tumor y su uso en la inmunoterapia contra el cáncer (divisional solicitud 201702346)
CL2021000624A CL2021000624A1 (es) 2015-03-17 2021-03-15 Péptidos asociados a tumor que se unen al complejo mayor de histocompatibilidad (mhc) y/o inducen la reacción cruzada de linfocitos t y sus usos en la inmunoterapia contra el cáncer (divisional de la solicitud no. 201702346)
CL2021000623A CL2021000623A1 (es) 2015-03-17 2021-03-15 Péptidos asociados a tumor y sus usos en la inmunoterapia contra el cáncer (divisional de la solicitud no. 201702346)

Country Status (14)

Country Link
US (15) US10449239B1 (es)
JP (3) JP6990935B2 (es)
KR (1) KR20240151873A (es)
AU (1) AU2020220071B2 (es)
CL (5) CL2017002346A1 (es)
CO (1) CO2017009101A2 (es)
CR (1) CR20210232A (es)
HK (1) HK1247842A1 (es)
IL (2) IL254081B (es)
MX (1) MX2022005570A (es)
MY (3) MY190083A (es)
PH (1) PH12017501467A1 (es)
TW (2) TWI755157B (es)
ZA (1) ZA201705219B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12214025B2 (en) 2015-03-17 2025-02-04 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX381241B (es) * 2015-04-27 2025-03-12 Cancer Research Tech Ltd Composición de células t para usarse en el tratamiento del cáncer.
GB201516047D0 (en) 2015-09-10 2015-10-28 Cancer Rec Tech Ltd Method
PH12022551111A1 (en) 2015-10-05 2023-08-23 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
CN116355851B (zh) * 2023-03-13 2023-09-08 广州医科大学附属第一医院（广州呼吸中心） 一种来源于人非小细胞肺癌的原代细胞株及其制备方法与应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5610031A (en) 1993-10-27 1997-03-11 The General Hospital Corporation B1k chain of laminin and methods of use
US6316213B1 (en) 1997-03-19 2001-11-13 The Board Of Trustees Of The University Of Arkansas Methods for the early diagnosis of ovarian, breast and lung cancer
US20030064072A9 (en) 1999-03-12 2003-04-03 Rosen Craig A. Nucleic acids, proteins and antibodies
WO2002012331A2 (en) 2000-08-07 2002-02-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of pancreatic cancer
EP1345006A4 (en) 2000-11-15 2006-05-31 Nat Inst Of Advanced Ind Scien BASIC INFORMATION DISTRIBUTION SYSTEM AREA
WO2003010327A2 (en) 2001-02-21 2003-02-06 Curagen Corporation Novel proteins and nucleic acids encoding same
AT5718U1 (de) 2001-06-22 2002-10-25 Voest Alpine Bergtechnik Verfahren zum ermitteln und bewerten von abbauverfahren sowie vorrichtung zur durchführung dieses verfahrens
JP2003321494A (ja) * 2002-02-26 2003-11-11 Daiichi Fine Chemical Co Ltd プロｍｍｐ−７の活性化調節方法
CA2500687A1 (en) 2002-10-02 2004-04-15 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20060252922A1 (en) 2002-12-04 2006-11-09 Macina Roberto A Compositions, splice variants and methods relating to colon specific genes and proteins
SI1760089T1 (sl) 2005-09-05 2009-12-31 Immatics Biotechnologies Gmbh S tumorjem povezani peptidi, ki se veĹľejo na molekule humanega levkocitnega antigena (HLA) razreda I ali II in ustrezno cepivo proti raku
HUE025636T2 (en) 2007-07-27 2016-04-28 Immatics Biotechnologies Gmbh Novel immunogenic epitopes for immunotherapy
RS54204B1 (sr) 2007-07-27 2015-12-31 Immatics Biotechnologies Gmbh Nova imunoterapija protiv tumora mozga
WO2009075883A2 (en) * 2007-12-12 2009-06-18 University Of Georgia Research Foundation, Inc. Glycoprotein cancer biomarker
WO2010021822A2 (en) * 2008-07-30 2010-02-25 The Regents Of The University Of California Discovery of candidate biomarkers of in vivo apoptosis by global profiling of caspase cleavage sites
ES2536465T3 (es) 2008-10-01 2015-05-25 Immatics Biotechnologies Gmbh Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres
US8568996B2 (en) 2008-10-21 2013-10-29 University of Pittsburgh—of the Commonwealth System of Higher Education MMP activation peptide detection in biological samples
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
HK1197276A1 (en) * 2011-06-22 2015-01-09 Oncocyte Corporation Methods and compositions for the treatment and diagnosis of bladder cancer
AU2012301664A1 (en) 2011-08-31 2014-02-27 Oncocyte Corporation Methods and compositions for the treatment and diagnosis of cancer
US20140065620A1 (en) 2011-12-29 2014-03-06 Mayo Foundation For Medical Education And Research Nucleic acids for detecting breast cancer
US20150072349A1 (en) * 2012-03-16 2015-03-12 University Health Network Cancer Biomarkers and Methods of Use
US20140001546A1 (en) 2012-06-29 2014-01-02 Hubert M. Bode Semiconductor device and driver circuit with a current carrying region and isolation structure interconnected through a resistor circuit, and method of manufacture thereof
EP2806274A1 (en) * 2013-05-24 2014-11-26 AIT Austrian Institute of Technology GmbH Lung cancer diagnostic method and means
TWI714869B (zh) 2013-08-05 2021-01-01 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物
GB201423361D0 (en) * 2014-12-30 2015-02-11 Immatics Biotechnologies Gmbh Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides
GB201504502D0 (en) 2015-03-17 2015-04-29 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
CR20210232A (es) 2015-03-17 2022-06-24 Immatics Biotechnologies Gmbh NUEVOS PÉPTIDOS Y NUEVA COMBINACIÓN DE PÉPTIDOS PARA EL USO EN LA INMUNOTERAPIA CONTRA EL CÁNCER DE PÁNCREAS Y OTROS TIPOS DE CÁNCER (Divisional 2017-0419)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12214025B2 (en) 2015-03-17 2025-02-04 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
US12295994B2 (en) 2015-03-17 2025-05-13 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
US12295996B2 (en) 2015-03-17 2025-05-13 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
US12295995B2 (en) 2015-03-17 2025-05-13 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers

Also Published As

Publication number Publication date
US12295994B2 (en) 2025-05-13
US20190388530A1 (en) 2019-12-26
IL254081B (en) 2022-06-01
US11007258B2 (en) 2021-05-18
CR20210232A (es) 2022-06-24
JP7478718B2 (ja) 2024-05-07
US20230065320A1 (en) 2023-03-02
KR20240151873A (ko) 2024-10-18
MY199500A (en) 2023-11-01
AU2020220071B2 (en) 2022-06-02
US10561718B2 (en) 2020-02-18
HK1247842A1 (zh) 2018-10-05
ZA201705219B (en) 2019-06-26
US20190314473A1 (en) 2019-10-17
US12295996B2 (en) 2025-05-13
TWI755158B (zh) 2022-02-11
US20210228698A1 (en) 2021-07-29
US11116826B2 (en) 2021-09-14
TW202124428A (zh) 2021-07-01
US20210322527A1 (en) 2021-10-21
CL2018002427A1 (es) 2018-10-12
US10729755B1 (en) 2020-08-04
JP6990935B2 (ja) 2022-02-15
TWI755157B (zh) 2022-02-11
US20200147192A1 (en) 2020-05-14
MY190083A (en) 2022-03-25
JP2022046465A (ja) 2022-03-23
CL2020001675A1 (es) 2020-09-25
PH12017501467A1 (en) 2018-01-15
US20250235519A1 (en) 2025-07-24
AU2020220071A1 (en) 2020-09-03
US20200316183A1 (en) 2020-10-08
CL2021000623A1 (es) 2021-07-23
US10449239B1 (en) 2019-10-22
US20190388531A1 (en) 2019-12-26
MY199259A (en) 2023-10-23
US20200405830A1 (en) 2020-12-31
US10898561B2 (en) 2021-01-26
JP2024041860A (ja) 2024-03-27
US20200338175A1 (en) 2020-10-29
US12295995B2 (en) 2025-05-13
US20230051035A1 (en) 2023-02-16
IL280879A (en) 2021-04-29
CL2021000624A1 (es) 2021-08-06
US10668138B1 (en) 2020-06-02
MX2022005570A (es) 2022-06-09
CO2017009101A2 (es) 2017-11-30
US20200268861A1 (en) 2020-08-27
IL254081A0 (en) 2017-10-31
US20200230222A1 (en) 2020-07-23
US10576135B2 (en) 2020-03-03
US12214025B2 (en) 2025-02-04
US10792350B2 (en) 2020-10-06
US11007257B2 (en) 2021-05-18
TW202124417A (zh) 2021-07-01
US20230094790A1 (en) 2023-03-30
JP2020120659A (ja) 2020-08-13

Similar Documents

Publication Publication Date Title
CL2023001346A1 (es) Uso de péptidos en inmunoterapia contra cáncer de pulmón amicrocítico y otros.
CO2018002202A2 (es) Péptidos y combinaciones de péptidos para inmunoterapia contra el cáncer de próstata y otros tipos de cáncer
CL2018000780A1 (es) Péptidos y combinación de péptidos para el uso en la inmunoterapia contra el cáncer microcítico de pulmón y otros tipos de cáncer
CO2017012891A2 (es) Péptidos y combinaciones de péptidos para la inmunoterapia contra el cáncer de ovario y otros tipos de cáncer
CO2018003860A2 (es) Péptidos y combinación de péptidos para el uso en la inmunoterapia contra el cáncer de mama y otros tipos de cáncer
CO2017008902A2 (es) Péptidos y nuevas combinaciones de péptidos para inmunoterapia contra el cáncer de pulmón, incluido el cáncer de pulmón amicrocítico y otros tipos de cáncer
CO2018000245A2 (es) Péptidos y combinaciones de péptidos para inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer
CO2018000252A2 (es) Péptidos y combinaciones de péptidos para inmunoterapia contra el cáncer epitelial de ovario y otros tipos de cáncer
CR20180245A (es) Nuevos péptidos y combinación de péptidos para el uso en la inmunoterapia contra varios tipos de cáncer
CR20180001A (es) Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de ovario y otros tipos de cáncer.
CR20180051A (es) Nuevos epítopos celulares y nuevas combinaciones de epítopos celulares para el uso en la inmunoterapia del mieloma y de otros tipos de cáncer.
CR20180398A (es) Péptidos, combinaciones de péptidos y células para el uso en la inmunoterapia contra el cáncer de vejiga y otros tipos de cáncer
CR20210234A (es) NUEVOS PÉPTIDOS Y NUEVA COMBINACIÓN DE PÉPTIDOS PARA EL USO EN LA INMUNOTERAPIA CONTRA EL CÁNCER DE PÁNCREAS Y OTROS TIPOS DE CÁNCER (Divisional 2017-0419)
MX2018009958A (es) Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra el linfoma no hodgkiniano (lnh) y otros tipos de cancer.
CR20200493A (es) NUEVOS PÉPTIDOS, COMBINACIONES DE PÉPTIDOS Y SOPORTES PARA EL USO EN EL TRATAMIENTO INMUNOTERAPÉUTICO DE VARIOS TIPOS DE CÁNCER (Divisional 2018-174)
CO2019012077A2 (es) Péptidos y combinaciones de los mismos para el uso en la inmunoterapia contra diversos tipos de cáncer
CL2018000545A1 (es) Nuevos péptidos, combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer.
CO2017009922A2 (es) Péptidos y combinación de péptidos para inmunoterapia contra diversos tumores
CO2018012294A2 (es) Inmunoterapia contra el melanoma y otros tipos de cáncer
CO2017010830A2 (es) Péptidos y combinaciones de péptidos y de soportes
CO2018004869A2 (es) Péptidos y combinación de péptidos para inmunoterapia contra varios tipos de cáncer
CO2018000247A2 (es) Nuevos epítopos celulares y nuevas combinaciones de epítopos celulares para el uso en la inmunoterapia del mieloma y de otros tipos de cáncer
MX2022005570A (es) Nuevos peptidos y nueva combinacion de peptidos para el uso en la inmunoterapia contra el cancer de pancreas y otros tipos de cancer.
CL2021001010A1 (es) Péptidos y combinación de péptidos para el uso en la inmunoterapia contra el cáncer microcítico de pulmón y otros tipos de cáncer (divisional de la solicitud no. 201800780)
AR122217A2 (es) Péptidos y soportes útiles en el tratamiento inmunoterapéutico de varios tipos de cáncer